SuperworthGilead Sciences, Inc. GILD
Drug Manufacturers - General, Healthcare
$146.85
+1.82%
- Market cap
- $182.1B
- PE
- —
- 10y median 19.2×
- Forward PE
- Price to sales
- 6.0×
- EV/EBIT
- 22.2×
- Revenue, 12 months
- $30.5B
- +6% on a year ago
- Net margin
- −10.6%
- Free cash flow yield
- 7.1%
Gilead Sciences trades at 6.0× sales. Its trailing earnings are negative, so it has no PE. Revenue was $30.5B over the last twelve months, up 6% on a year earlier with a −11% net margin.
Charts
Financials
| Income statement | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| $7.1B | $6.7B | $7B | $7.5B | $7.6B+6% | $6.7B−0% | $7.1B+2% | $7.8B+3% | $7.9B+5% | $7B+4% | $7.8B+10% | |
| Cost of revenue | $2.1B | $1.6B | $1.5B | $1.6B | $1.6B−24% | $1.5B−1% | $1.5B−3% | $1.6B−0% | $1.6B+3% | $1.4B−6% | $1.6B+5% |
| Gross profit | $5B | $5.1B | $5.4B | $6B | $6B+19% | $5.1B−0% | $5.6B+3% | $6.2B+4% | $6.3B+5% | $5.5B+8% | $6.2B+12% |
| R&D | $1.4B | $1.5B | $1.4B | $1.4B | $1.6B+17% | $1.4B−9% | $1.5B+10% | $1.3B−4% | $1.6B−4% | $1.4B−1% | $1.8B+18% |
| SG&A | $1.6B | $1.4B | $1.4B | $1.4B | $1.9B+19% | $1.3B−9% | $1.4B−1% | $1.4B−5% | $1.8B−6% | $1.5B+15% | $1.9B+41% |
| $1.6B | −$4.3B | $2.6B | $888M | $2.5B+52% | $2.2B | $2.5B−6% | $3.3B+275% | $2B−19% | $2.6B+16% | −$10.4B | |
| Interest expense | $252M | $254M | $237M | $238M | $249M−1% | $260M+2% | $254M+7% | $256M+8% | $255M+2% | $240M−8% | $247M−3% |
| Pre-tax income | $1.7B | −$4.5B | $2.1B | $956M | $2.2B+31% | $1.6B | $2.4B+18% | $3.6B+281% | $2.1B−4% | $2.6B+57% | −$10.3B |
| $237M | −$315M | $438M | −$297M | $385M+62% | $334M | $468M+7% | $589M | −$105M | $559M+67% | $242M−48% | |
| Net income | $1.4B | −$4.2B | $1.6B | $1.3B | $1.8B+25% | $1.3B | $2B+21% | $3.1B+144% | $2.2B+22% | $2B+54% | −$10.5B |
| $1.14 | −$3.34 | $1.29 | $1.00 | $1.42+25% | $1.04 | $1.56+21% | $2.43+143% | $1.74+23% | $1.61+55% | −$8.45 | |
| 1.3B | 1.2B | 1.3B | 1.3B | 1.3B+0% | 1.3B+1% | 1.3B+0% | 1.3B+0% | 1.3B−1% | 1.3B−0% | 1.2B−1% |
From each company's 10-Q and 10-K filings. Fiscal years are four fiscal quarters added up; balance sheet lines are as of the period's end. Growth is on the same period a year earlier.
Estimates
Next earnings report: .
Analyst consensus for the next eight quarters, with the range from the lowest to the highest estimate, is part of Superworth Pro.
Peers
Companies in Drug Manufacturers - General within ten times Gilead Sciences's size, closest in size first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| GILDGilead Sciences, Inc. | $182.1B | — | 19.2× | 6.0× | +6% | −10.6% | |
| PFEPfizer Inc. | $159.6B | 36.8× | 16.3× | 2.5× | −0% | 6.8% | |
| AMGNAmgen Inc. | $223.3B | 25.7× | 21.0× | 5.9× | +9% | 23.0% | |
| BMYBristol-Myers Squibb Company | $122B | 13.1× | 19.9× | 2.5× | +3% | 18.9% | |
| MRKMerck & Co., Inc. | $352.3B | 114× | 25.7× | 5.3× | +5% | 4.8% | |
| ABBVAbbVie Inc. | $479.5B | 76.7× | 27.5× | 7.4× | +10% | 9.8% | |
| JNJJohnson & Johnson | $622.8B | 29.9× | 24.2× | 6.4× | +8% | 21.5% | |
| BIIBBiogen Inc. | $32.8B | 39.3× | 16.1× | 3.3× | +0% | 8.3% | |
| LLYEli Lilly and Company | $1.1T | 39.9× | 41.3× | 14.0× | +50% | 33.5% | |
| Peer median | $287.8B | 38.1× | 22.6× | 5.6× | +6% | 14.3% |
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .